EUVIMEDEUVIMED entdecken
Crossref

Allergen Immunotherapy under protective biological treatment with Omalizumab

Michael Krokenberger, Sebastian Kotz, Barbara Wollenberg, Adam Chaker

Laryngo-Rhino-Otologie · 01.05.2024 · 103 (S 02 S 02) · S322-S323

DOI: 10.1055/s-0044-1785093 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Laryngo-Rhino-Otologie, erschienen am 01.05.2024. Verfasst von Michael Krokenberger und 3 weiteren Autor:innen.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Omalizumab (Xolair®​; Novartis) is a recombinant IgG1 monoclonal antibody that selectively binds to human IgE and is approved for the treatment of allergic asthma, chronic spontaneous urticaria, and chronic rhinosinusitis with nasal polyps. Since its approval, the use of Omalizumab has been investigated in clinical studies for food allergies, atopic dermatitis, and eosinophilic gastritis. However, no approval exists for these indications. Allergen immunotherapy (AIT) is the only causal therapy used for allergic rhinitis (AR) and asthma. Systemic side effects are rare but can limit therapy. Material and methods We present 5 patient cases as use-cases over the long term for the targeted use of Omalizumab in AIT.

Results

Over a period of 2 to 5 years, none of the patients showed a severe anaphylactic reaction. Isolated skin redness at the injection site occurred occasionally. Rhinoconjunctival symptoms regressed while comorbid conditions such as asthma or chronic spontaneous urticaria improved simultaneously.

Conclusion

Simultaneous administration of Omalizumab enables a subcutaneous AIT with fewer side effects. The presented results show that in cases of T2 comorbidities otherwise not adequately controlled or severe side effects under AIT, the administration of Omalizumab is a rational option. Publication History Article published online: 19 April 2024 © 2024. Thieme. All rights reserved. Georg Thieme Verlag KG Rüdigerstraße 14, 70469 Stuttgart, Germany

Zitieren

APA

Krokenberger, M., Kotz, S., Wollenberg, B., & Chaker, A. (2024). Allergen Immunotherapy under protective biological treatment with Omalizumab. Laryngo-Rhino-Otologie, 103(S 02 S 02), S322-S323. https://doi.org/10.1055/s-0044-1785093

Vancouver

Krokenberger M, Kotz S, Wollenberg B, Chaker A. Allergen Immunotherapy under protective biological treatment with Omalizumab. Laryngo-Rhino-Otologie. 2024;103(S 02 S 02):S322-S323. doi:10.1055/s-0044-1785093

BibTeX
@article{Krokenberger2024,
  author = {Krokenberger, Michael and Kotz, Sebastian and Wollenberg, Barbara and Chaker, Adam},
  title = {Allergen Immunotherapy under protective biological treatment with Omalizumab},
  journal = {Laryngo-Rhino-Otologie},
  year = {2024},
  volume = {103},
  number = {S 02 S 02},
  pages = {S322--S323},
  doi = {10.1055/s-0044-1785093}
}
Kostenlos starten →